VIDEO: Cabozantinib regimen 'reasonably well tolerated,' not effective over monotherapy
Cabozantinib combined with nivolumab and ipilimumab was "reasonably well tolerated," though it did not display an efficacy advantage over monotherapy, Bhavana Konda, MD, MPH, said in an interview with Healio.
In this video, Konda, a medical oncology specialist at The Ohio State University Comprehensive Cancer Center, discusses the results of a study presented at American Thyroid Association Annual Meeting.
A 2-week cycle of cabozantinib (Cabometyx/Cometriq, Exelis) monotherapy was administered, followed by a triple therapy regimen of cabozantinib, nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) every 6 weeks for 24 weeks. Following the 24-week mark, ipilimumab therapy ceased, while cabozantinib and nivolumab treatment continued, Konda said.
The primary endpoint of the study was objective response rate within the first 6 months.
"Out of 11 patients who were enrolled into stage 1 of the study, across six sites in the United States, we had two partial responses overall," , Konda said.
She said they found a median progression-free survival rate of 9 months and 19.2 months for the median overall survival.
Collapse
Healio Interviews